Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14769895 | 0.92 | GAA (0.43) | MAPTKMT2AHTTBCHENPSR1 | |
| SCHEMBL28760946 | 0.87 | MAPT (0.42) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL28470785 | 0.84 | BCHE (0.45) | MAPTLMNAL3MBTL1KMT2AHTT | |
| SCHEMBL28499108 | 0.79 | BCHE (0.40) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL17560689 | 0.79 | NPC1 (0.40) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL2505924 | 0.79 | NPC1 (0.40) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL4261396 | 0.79 | NPC1 (0.40) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL14847321 | 0.79 | GAA (0.43) | MAPTKMT2AHTTBCHENPSR1 | |
| SCHEMBL28914333 | 0.78 | NPC1 (0.39) | MAPTLMNAL3MBTL1NPC1RAB9A | |
| SCHEMBL28410806 | 0.78 | NPC1 (0.39) | MAPTLMNAL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422710-B | Preparation method of sofosbuvir fluorolactone intermediate | 常州制药厂有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-109422710-B | Preparation method of sofosbuvir fluorolactone intermediate | 常州制药厂有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-109422710-B | Preparation method of sofosbuvir fluorolactone intermediate | 常州制药厂有限公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2019041317-A1 | METHOD FOR PREPARING SOFOSBUVIR FLUOROLACTONE INTERMEDIATE | 常州制药厂有限公司 | 2019-03-07 | — | — | WO | disclosed |